Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation

Join Michael Mullen, Federico De Marco, and Philipp Lurz as they discuss the latest breakthroughs in the treatment of mitral and tricuspid regurgitation at EuroPCR 2025. In this roundtable session, they delve into both repair and replacement techniques, offering insights into new systems and their impact on clinical practice.

With the recent approval of the first transcatheter transseptal mitral replacement system, the SAPIEN M3, the discussion covers its use, the success of the first commercial case, and its promising outcomes. Key benefits of the system include significant time savings and the potential to expand treatment options for patients.

In the tricuspid space, the introduction of a TTVR system for tricuspid replacement is changing practice on multiple fronts, from improving treatment results to broadening the patient population. This approach also makes replacement a more viable option for complex cases.

The session also explores the evolving decision-making process between repair and replacement, how the advent of transcatheter mitral replacement is reshaping both practice and patient outcomes, and the growing trend towards tailoring procedures in the future.

Watch the full roundtable for key updates on this fast-evolving area of mitral and tricuspid intervention.

This interview was filmed at EuroPCR 2025: see more videos here.